Innovations in the treatment of arvi in children
https://doi.org/10.21518/2079-701X-2018-17-89-93
Abstract
The authors presented an analytical review of domestic and foreign literature on the clinical efficacy and safety of release-active drug in the treatment and prevention of acute respiratory infections in children.
About the Authors
Yu. L. Mizernitsky
Veltischev Research Clinical Institute of Pediatrics, autonomous structural subdivision of Pirogov National Research Medical University (RNIMU), Ministry of Health of Russia
Russian Federation
Moscow
Russian Federation
Moscow
I. M. Melnikova
Yaroslavl State Medical University, Federal State Budgetary Educational Institution of Higher Education of the Ministry of Health of Russia
Russian Federation
Yaroslavl
Russian Federation
Yaroslavl
References
1. On the state of sanitary and epidemiological welfare of the population in the Russian Federation in 2016: State report. M.: Federal Service for Supervision of Consumer Rights Protection and Human Welfare, 2017. 220 p.
2. Savenkova MS. Influenza and other acute respiratory viral infections in children. Aspects of antiviral therapy. Klinicheskaya i Neotlozhnaya Pediatriya: Novosti, Mneniya, Obuchenie, 2015, 1. http://pediatrnmo.geotar.ru/ru/jarticles_ped/8.html?SSr=0901337a1e01ffffffff27c__07df080e01091240fa
3. Pavia AT. Viral Infections of the Lower Respiratory Tract: Old Viruses, New Viruses, and the Role of Diagnosis. Clinical Infectious Diseases, 2011, 52(4): 284-289.
4. Ovsyannikova EM, Korovina NA, Morgunova SL, Stoyko TYu, Bodarevskaya OP. Rational therapy of acute respiratory infections and flu. Meditsinsky Sovet, 2015, 1: 66-70.
5. Kniazheskaya NP, Baranova IA, Fabrika MP. New possibilities of treatment and prevention of ARVI in patients with chronic obstructive pulmonary diseases. Meditsinsky Sovet, 2017, 5: 38-41.
6. Prikhodko AG, Perelman YuM, Kolosov VP. Airway hyperreactivity. Vladivostok: Dalnauka, 2011. 204 p.
7. Kostinov MP. Vaccination of children with impaired health. M.: 4Mpress, 2013. 432 p.
8. Rozy A, Chorostowska-Wynimko J. Bacterial immunostimulants -mechanism of action and clinical application in respiratory diseases. Pneumonol Alergol Pol, 2008, 76(5): 353-9.
9. Krasnova EI, Loskutova SA, Panasenko LM. Modern approach to antiviral treatment of acute respiratory viral infections in children. How to avoid polypragmasy? Lechashchy Vrach, 2014, 10. http://www.lvrach.ru/2014/10/15436073/
10. Mizernitsky YuL. The use of innovative domestic interferon inducer for the prevention and treatment of acute respiratory viral infections in children. Meditsinsky Sovet, 2016, 1: 22-25.
11. Mizernitsky YuL, Melnikova IM. Acute respiratory infections in children: a problem of polypragmasy. Meditsinsky Sovet, 2016, 16: 64-67.
12. WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and Other Influenza Viruses. https: // www.ncbi.nlm.nih.gov/books/NBK138515/
13. Zaplatnikov AL, Burtseva EI, Girina AA, Korovina NA, Kirillova ES, Feodoritova EL, Lepiseva IV, Svintsitskaya VI. Etiotropic therapy of influenza and other acute respiratory viral infections in children. Consilium Medicum, 2016, 18 (11): 83-86.
14. Afanasyeva, OI, Esaulenko EV. A look at the efficacy of release-active antiviral drugs in the treatment of influenza and ARVI through the lens of evidence-based medicine. Consilium Medicum, 2016, 03: 18-21.
15. Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, Iskander JK, Wortley PM, Shay DK, Bresee JS, Cox NJ, Centers for Disease Control and Prevention (CDC) Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep, 2010 Aug 6, 59(RR-8): 1-62.
16. Orlova NV. Acute respiratory viral infections in therapeutic practice. Trudny Patsient, 2013, 11 (4): 22-27.
17. Averyanov AV, Babkin AP, Bart BYa, Volchetsky AL, Minina ES, Kozyrev OA, Kostinov MP, Petrov DV, Selkova EP, Putilovsky MA, Nechaev VV, Epstein OI, Andrianova EN. Ergoferon and Oseltamivir in the treatment of influenza: the results of multicenter comparative randomized clinical trial. Antibiotiki i Khimioterapiya, 2012, 57 (7-8): 23-30.
18. Epstein OI. Release-activity: from the phenomenon to the creation of new drugs. Byul. Exper. Biol. i Med., 2012, 7: 62-67.
19. Epstein OI. The phenomenon of release-activity and hypothesis of “spatial” homeostasis. Uspekhi Fiziologicheskikh Nauk, 2013, 44 (3): 54-76.
20. Zhavbert, ES, Dugina, YuL, Epstein OI. Anti-inflammatory and antiallergic properties of histamine antibodies in releaseactive form: a review of experimental and clinical studies. Detskie Infektsii, 2014, 1: 40-43.
21. Mizernitsky YuL, Melnikova IM, Kozlova LA, Dorovskaya NL, Lysanova MA, Kindyakova EI, Chistyakova TG, Kuznetsova EA. The efficacy of the combined drug of ultra-low doses of antibodies to inflammatory mediators in dry cough in children with respiratory infections. Pulmonology of childhood: problems and solutions. M: Medpraktika-M, 2014, Issue 14: 95-99.
22. Mizernitsky YuL, Melnikova IM. The modern paradigm of managing patients with cough. Meditsinsky Sovet, 2016, 15: 67-71.
23. Dolinina LYu. The advantages of using ergoferon and anaferon in the prevention and treatment of ARVI and influenza. Arkhiv Vnutrenney Meditsiny, 2015, 1 (21): 38-40.
24. Shilovsky IP. The use of combined drugs in the treatment of respiratory viral infections. Meditsinsky Sovet, 2016, 17: 45-48.
25. Dmitriev AN. Releaseactive drugs: a new direction in the treatment of acute respiratory viral infections (literature review). Prakt. Meditsina, 2014, 7 (83): 14-20.
26. Usenko DV. Ergoferon: results of clinical studies in ARVI in children. Praktika Pediatra, 2015, 4: 66-70.
27. Kniazheskaya NP, Baranova IA, Fabrika MP, Belevsky AS. New possibilities of treatment and prevention of ARVI in patients with chronic obstructive pulmonary diseases. Atmosfera. Pulmonologiya i Allergologiya, 2012, 3: 16-20.
28. Geppe NA, Kondyurina EG, Galustyan AN, Pak TE, Baltserovich NB, Zhiglinskaya OV, Kamaev AV, Lazareva SG, Laleko SL, Melnikova IM, Perminova OA, Sabitov AU. Liquid dosage form of ergoferon: effective and safe drug to treat acute respiratory infections in children. Intermediate results of multicenter, double-blind, placebo-controlled, randomized clinical trial. Antibiotiki i Khimioterapiya, 2014, 59 (5-6): 6-14.
29. Geppe NA, Valiyeva STK, Faradzheva NAG., Oganyan MR, Myrzabekova GT, Zhanuzakov MA, Katarbaev AK, Skuchalina LN, Aytkuluyev NS, Kabaeva DD, Raupov FO, Ibadova GA, Shamsiev FS, Navruzova ShI, Khusinova ShA., Nurmukhamedova RA, Abdrakhmanova ST. Treatment of ARVI and influenza in outpatient practice: results of international observational non-intervention HERMITAGE program. Terapia, 2017, 8 (18): 63-78.
30. Tikhonova, EP, Kuzmina TYu, Andronova, NV, Tikhonova, YuS. The efficacy of ergoferon for the treatment of acute respiratory viral infections. Prakticheskaya Meditsina, 2014, 1 (77): 179-184.
31. Kramarov SO, Zakordonets LV. Experience in using Ergoferon in children with acute respiratory viral infections. Sovremennaya Pediatriya, 2014, 8 (64): 1-4.
Review
For citations:
Mizernitsky YL, Melnikova IM. Innovations in the treatment of arvi in children. Meditsinskiy sovet = Medical Council. 2018;(17):89-93. (In Russ.) https://doi.org/10.21518/2079-701X-2018-17-89-93
Views:
892
Email this article 